Scholars Central

Conference abstractPublished 20 Jun 2016

Next generation targeted recombinant human cytolytic fusion proteins

Authors: Stefan Barth

University of Cape Town, South Africa

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Targeted immunotherapeutics, such as antibody drug conjugates (ADCs) or immunotoxins (ITs) represent promising agents for treatment of cancer. Despite their encouraging performance in clinical trials, both ADCs and ITs suffer from disadvantages like stoichiometrically undefined chemical linkage of the cytotoxic payload and potential immunogenicity of bacteria or plant derived toxins in humans, respectively. Therefore, we designed a number of targeted recombinant cytolytic fusion proteins, replacing bacterial toxins like Pseudomonas exotoxin A by human enzymes/protein derived from proteases, kinases, RNases and microtubule associated proteins. This presentation will summarize the latest results on the next generation of targeted fully human recombinant cytolytic fusion proteins.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Pharmaceutical Care & Health Systems.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmaceutical Care & Health Systems
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Stefan Barth”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels